Bone drug may shield cancer survivors from crippling fractures
NCT ID NCT07245381
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether alendronate, a drug used for osteoporosis, can prevent pelvic fractures in cervical cancer patients who have had chemotherapy and radiation. About 65 adults with non-metastatic cervical cancer will receive alendronate to see if it strengthens bones and reduces fracture risk. The goal is to improve quality of life and reduce pain after cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment